1128results about How to "Retain activity" patented technology

Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures.

A composition of enzyme, polymer, and crosslinker forms a network of covalently bound macromolecules. The covalently immobilized enzyme preparation has enzymatic activity, and retains stable activity when dried and stored at ambient conditions. Methods for preparing an immobilized enzyme and methods for using the enzyme are disclosed.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

Modified human growth hormone polypeptides and uses thereof are provided.

Several diterpene glycosides (e.g., rubusoside, rebaudioside, steviol monoside and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, and celecoxib. The use of the diterpene glycoside rubusoside increased solubility in all tested compounds. The diterpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries. Aqueous solutions by using rubusoside to increase the solubility of otherwise insoluble drugs will have several new routes of administration. In addition, aqueous solutions of therapeutic compounds with rubusoside were shown to retain the known pharmacological activity of the compounds.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

A stable liquid medical formulation containing an antibody is provided, which contains a therapeutically effective amount of an antibody in a glutamate buffer and / or a citrate buffer and has a pH between 4.0 and 6.0.

The invention relates to a fermentation method for production of nutritionally balanced natural fruit enzymes. The method comprises the following steps: (1) pretreatment on raw materials; (2) a first bacterium inoculation: inoculating a saccharomyces cerevisiae liquor with concentration of 106 CFU / ml into a pulp according to an inoculation proportion of 5%; (3) early stage fermentation; (4) a secondary bacterium inoculation: after the early fermentation, inoculating acetic acid bacterium liquid and lactic acid bacterium liquid in a weight ratio of 1:1 for a secondary bacterium inoculation according to an inoculation amount of 5%; (5) middle-term fermentation; (6) coarse filtration; (7) secondary fermentation; (8) ripening; and (9) fine filtration to obtain the natural fruit enzyme. The fermentation method provided by the invention through low-temperature sterilization and strict control on the fermentation temperature retains the enzyme activity to the maximum; and twice inoculation of dominant bacteria effectively inhibits breeding of other infectious microbes, so as to realize stable product quality.

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antimicrobial activity in vivo.

Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens. A novel strain of Bacillus subtilis was isolated from the gastrointestinal tract of poultry and was found to produce a factor or factors that have excellent inhibitory effects on Clostridium perfringens, Clostridium difficile, Campylobacter jejuni, Campylobacter coli, and Streptococcus pneumoniae. The factor(s) retain full viability and antimicrobial activity after heat treatment. The invention provides a method of treatment of pathogenic microorganisms including C. perfringens.

The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type n diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.

The present invention relates to spray-dried amorphous powders which contain a pharmaceutical active substance and a matrix-forming agent, preferably a polymer, sugar or sugar alcohol in an amount of ≧20-60% (w / w). The powders have a moisture content which is less than 1.2% (w / w), preferably less than 1% (w / w). The present invention also relates to special methods of preparing such powders and methods of administering them by inhalation.

The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.

The invention relates to an innocent treatment method for animal carcasses died of illness and organic wastes. The innocent treatment method comprises the following steps: collecting to-be-treated materials of animal carcasses died of illness and organic wastes, then, mixing the to-be-treated materials and auxiliary materials as organic matters including wood flour and rice husk, and next, supplementing water until the water content is up to 50-60%; adding a compound microorganism preparation into a treatment tank; carrying out micro-biological degradation so as to ensure that main components such as the animal carcasses died of illness, various organic wastes and the like can be completely degraded within 24 hours and can be processed into an available organic fertilizer. The innocent treatment method is reasonable in process, simple and convenient in operation, energy-saving, environment-friendly, pollution-free and capable of utilizing the animal carcasses died of illness and the organic wastes as fertilizers.

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

The present invention relates to polypeptide-polymer conjugates having added and / or removed one or more attachment groups for coupling polymeric molecules on the surface of the polypeptide structure, a method for preparing polypeptide-polymer conjugates of the invention, the use of said conjugates for reducing the immunogenicity and allergenicity and compositions comprising said conjugate.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The present inventors revealed that deamidation of an antibody can be suppressed without influencing its activity by substituting a glycine that is located adjacent to an asparagine with another amino acid.

Modified growth hormone polypeptide and uses thereof are provided.

In one aspect, the invention provides a purified and modified phytase enzyme from Escherichia coli K12 appA phytase. The enzyme has phytase activity and improved thermal tolerance as compared with the wild-type enzyme. In addition, the enzyme has improved protease stability at low pH. Glycosylation of the modified phytase provided a further improved enzyme having improved thermal tolerance and protease stability. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In one aspect, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

The invention discloses a waste slurry recycling and reusing technology of a concrete mixing station. The waste slurry recycling and reusing technology of the concrete mixing station comprises the following steps: firstly pre-treating waste slurry of the concrete mixing station, and maintaining the activity of a cementing material in the waste slurry; then conveying the waste slurry from a settling pond to a pre-homogenizing pond, adding water and stirring for carrying out waste slurry pre-homogenization; filtering the obtained homogenous waste slurry through a filter screen, and conveying the homogenous waste slurry to a burdening and stirring tank; metering and stirring cement, a mineral admixture, water, a water reducing agent, an early strength agent and an exciting agent according to a proportion to prepare concrete slurry, conveying the obtained concrete slurry to a foaming machine to prepare foam concrete, pouring the foam concrete in a mold, standing, demoulding, and maintaining, thus obtaining a regenerated foam concrete product with the dry density level of 600 to 800 kg / m<3>. According to the waste slurry recycling and reusing technology disclosed by the invention, the problems of waste of land resources, environment pollution and increment of running cost of the concrete mixing station due to backfilling of the waste slurry of the concrete mixing station can be solved, qualified regenerative products can be generated, and the waste slurry recycling and reusing technology is suitable for being popularized and applied.

The present invention relates to polypeptides with reduced immune response including reduced allergenicity having one or more amino acid residues being substituted with other amino acid residues and / or having coupled one or more polymeric molecules in the vicinity of the polypeptides metal binding site, a method for preparing modified polypeptides of the invention, the use of the polypeptide for reducing the immunogenicity and allergenicity and compositions comprising the polypeptide.

The invention contemplates a method of making a catalytic material, and uses of the material. The catalytic material is made by depositing catalytic metals, such as gold or platinum, on substrate materials, such as lanthanum-doped ceria or other oxides. The catalytic metal, which comprises both crystalline and non-crystalline structures, is treated, for example with aqueous basic NaCN solution, to leach away at least some of the crystalline metallic component. The remaining noncystalline metallic component associated with the substrate exhibits catalytic activity that is substantially similar to the catalyst as prepared. The use of the catalyst in an apparatus such as a reactor or analytic instrument is contemplated, as is the use of the catalyst in efficient, cost-effective reactions, such as removal of carbon monoxide from fuel gases, for example by performing the water gas shift reaction.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The invention discloses rhodiola rosea fermentation protoplasm cosmetic and a preparation method thereof. Efficient ingredients of the rhodiola rosea fermentation protoplasm cosmetic are supernate obtained by mixing powder of rhodiola rosea root, water and zymophyte to obtain an initial system, fermenting the initial system to obtain zymotic fluid and sterilizing and centrifuging the zymotic fluid. The zymophyte is saccharomycete. The rhodiola rosea root is subjected to whole plant fermentation by adopting the saccharomycete, all functional ingredients and activity of the plant are kept, and loss of active ingredients caused by an extracting method is avoided. Any organic reagents are not added during extraction, fermentation temperature and fermentation pH are mild, structure of plant active ingredients is not damaged, natural activity of the plant is kept, and chemical components of essence and the like are not added in the fermentation protoplasm so as to ensure the safety of products on the human body. The rhodiola rosea fermentation protoplasm cosmetic is rich in salidroside, arbutin and the like having activities of restraining tyrosinase activity and restraining melanin synthesis so as to have a relatively strong whitening function on skin and has a synergistic effect with the components in the fermentation filtrate simultaneously.

Modified growth hormone polypeptide and uses thereof are provided.

A catalyst that can be used for the production of hydrogen from hydrocarbon fuels in steam reforming processes contains an active metal of, e.g., at least one of Ir, Pt and Pd, on a catalyst support of, e.g., at least one of monoclinic zirconia and an alkaline-earth metal hexaaluminate. The catalyst exhibits improved activity, stability in both air and reducing atmospheres, and sulfur tolerance.